Cargando…
Present and future pharmacotherapeutic agents in heart failure: an evolving paradigm
Many conditions culminate in heart failure (HF), a multi‐organ systemic syndrome with an intrinsically poor prognosis. Pharmacotherapeutic agents that correct neurohormonal dysregulation and haemodynamic instability have occupied the forefront of developments within the treatment of HF in the past....
Autores principales: | Loudon, Brodie L, Noordali, Hannah, Gollop, Nicholas D, Frenneaux, Michael P, Madhani, Melanie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4882493/ https://www.ncbi.nlm.nih.gov/pubmed/26993743 http://dx.doi.org/10.1111/bph.13480 |
Ejemplares similares
-
Assessment of pulmonary artery pressure by echocardiography—A comprehensive review
por: Parasuraman, Sathish, et al.
Publicado: (2016) -
The Evolving Pharmacotherapeutic Landscape for the Treatment of Sickle Cell Disease
por: Ballas, Samir K.
Publicado: (2020) -
Heart Failure with Preserved Ejection Fraction: a Pharmacotherapeutic Update
por: Vaz-Salvador, Pedro, et al.
Publicado: (2022) -
Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction
por: Parasuraman, Sathish K., et al.
Publicado: (2019) -
The Future of Schizophrenia Pharmacotherapeutics: Not So Bleak
por: Carpenter, William T.
Publicado: (2012)